We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

28 hedge funds and large institutions have $6.17M invested in Biolase, Inc. in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

10% less capital invested

Capital invested by funds: $6.85M → $6.17M (-$680K)

26% less funds holding

Funds holding: 38 → 28 (-10)

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Holders
28
Holders Change
-10
Holders Change %
-26.32%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
3
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$31.4K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$19.4K
3
EIM
Essex Investment Management
Massachusetts
+$14.8K
4
Jane Street
Jane Street
New York
+$11.1K
5
Renaissance Technologies
Renaissance Technologies
New York
+$9.22K

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$31K
2
Marshall Wace
Marshall Wace
United Kingdom
-$27K
3
Charles Schwab
Charles Schwab
California
-$23K
4
HF
HRT Financial
New York
-$14.8K
5
VCM
Virtue Capital Management
Tennessee
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
TFO
26
Tarbox Family Office
California
$3K – – –
Koshinski Asset Management
27
Koshinski Asset Management
Illinois
$1.06K – – –
Bank of America
28
Bank of America
North Carolina
$1K – – –
APA
29
American Portfolios Advisors
New York
$141 – – –
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
– -$31K -32 Closed
Marshall Wace
31
Marshall Wace
United Kingdom
– -$27K -29 Closed
Charles Schwab
32
Charles Schwab
California
– -$23K -24 Closed
VCM
33
Virtue Capital Management
Tennessee
– -$14K -14 Closed
BCM
34
Bayesian Capital Management
New York
– -$8K -9 Closed
Victory Capital Management
35
Victory Capital Management
Texas
– -$8K -9 Closed
DA
36
DCM Advisors
New York
– -$6K -7 Closed
AI
37
Atom Investors
Texas
– -$6K -6 Closed
CFGS
38
Concourse Financial Group Securities
Alabama
– -$4.61K -5 Closed
VF
39
Virtu Financial
New York
– -$5K -5 Closed
Barclays
40
Barclays
United Kingdom
– -$2K -2 Closed
JP Morgan Chase
41
JP Morgan Chase
New York
– -$2K -2 Closed
Osaic Holdings
42
Osaic Holdings
Arizona
– -$1.84K -2 Closed
CA
43
CoreCap Advisors
Michigan
– -$1K – –
1
2

BIOL Hedge Fund Activity: Q1 2022 in Review

28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2022, worth a combined $6.17M — down 9.9% from $6.85M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BIOL and 3 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 10 added.

The largest buyer was Millennium Management, adding an estimated $31.4K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $31K sold.

  • 28 institutional investors held Biolase, Inc. (BIOL) as of Q1 2022, down from 38 in Q4 2021.
  • Funds reported $6.17M of Biolase, Inc. stock for Q1 2022, down 9.9% quarter-over-quarter.
  • 3 funds opened new Biolase, Inc. positions in Q1 2022 and 13 closed out, a net change of -10 holders.
  • The largest Biolase, Inc. buyer in Q1 2022 was Millennium Management, an estimated $31.4K added.
  • The largest Biolase, Inc. seller in Q1 2022 was Acadian Asset Management, an estimated $31K sold.

Based on aggregated 13F filings for Q1 2022.